XZP-3621

Main purpose: Quantitatively analyze the total radioactivity in excreta after a single oral administration of [14C]XZP-3621 in healthy subjects, and obtain the material balance data and main excretion pathways in the human body; Quantitatively analyze the total radioactivity in whole blood and plasma after a single oral administration of [14C]XZP-3621 in healthy subjects, obtain the pharmacokinetic parameters of total radioactivity in plasma, and investigate the distribution of total radioactivity in whole blood and plasma; Investigate the radioactive metabolite spectrum in plasma, urine and feces of healthy subjects after a single oral administration of [14C]XZP-3621, identify the main metabolites, and provide the main metabolic pathways and elimination pathways of XZP-3621 in the human body. Secondary purpose: Use the validated liquid chromatography tandem mass spectrometry (LC-MS/MS) to quantitatively analyze the concentrations of XZP-3621, metabolite XZP-5089 and other metabolites (if applicable) in plasma, and obtain the pharmacokinetic parameters of XZP-3621, metabolite XZP-5089 and other metabolites (if applicable) in plasma. To evaluate the safety of a single oral dose of [14C]XZP-3621 in healthy subjects.